

Inhaled nitric oxide improves the hepatopulmonary syndrome: a physiologic analysis

Samir Gupta,^{1,2,3} Rosalind Tang ,^{3,4} Abdul Al-Hesayen^{1,5}

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/thoraxjnl-2020-216128>).

¹Department of Medicine, University of Toronto, Toronto, Ontario, Canada

²Division of Respiratory, St Michael's Hospital, Toronto, Ontario, Canada

³Keenan Research Centre for Biomedical Science, St Michael's Hospital, Toronto, Ontario, Canada

⁴Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, UK

⁵Division of Cardiology, St Michael's Hospital, Toronto, Ontario, Canada

Correspondence to

Dr Samir Gupta, St Michael's Hospital, Toronto M5B 1W8, Ontario, Canada; Samir.Gupta@unityhealth.to

Received 5 September 2020

Revised 10 December 2020

Accepted 5 March 2021



© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Gupta S, Tang R, Al-Hesayen A. *Thorax* Epub ahead of print: [please include Day Month Year]. doi:10.1136/thoraxjnl-2020-216128

ABSTRACT

The hepatopulmonary syndrome (HPS) is defined by liver dysfunction, intrapulmonary vasodilatation and abnormal oxygenation. Hypoxaemia is progressive and liver transplant is the only effective treatment. Severe hypoxaemia is a life-threatening HPS complication, particularly after transplant. We evaluated gas-exchange and haemodynamic effects of invasive therapies in a consecutive sample of 26 pre-transplant patients. Inhaled nitric oxide significantly improved partial pressure of oxygen (12.4 mm Hg; $p=0.001$) without deleterious effects on cardiac output. Trendelenburg positioning resulted in a small improvement, and methylene blue did not, though individual responses were variable. Future studies should prospectively evaluate these strategies in severe post-transplant hypoxaemia.

INTRODUCTION

The hepatopulmonary syndrome (HPS) is defined by liver dysfunction, intrapulmonary vasodilatation and abnormal oxygenation.¹ It occurs in up to 32% of people with cirrhosis^{1 2} and carries a poor prognosis.³ Liver transplantation is the only established therapy.^{1 4} However, some patients develop refractory hypoxaemia precluding transplant, and severe post-transplant hypoxaemia (requiring 100% fraction of inspired oxygen to maintain oxygen saturation $\geq 85\%$) occurs in 12% of patients, carries a 45% mortality and accounts for 68% of post-operative HPS deaths.⁵ This complication is thought to be caused by a transient post-transplant exaggeration of underlying HPS pathophysiology.⁵ Reports of strategies to manage severe hypoxaemia in HPS are limited to case reports and small case series.² We sought to formally evaluate possible strategies in a cohort of stable pre-transplant patients with HPS.

METHODS

We retrospectively analysed consecutive patients from the Canadian HPS Programme (Toronto, Ontario) with moderate to very severe HPS ($\text{PaO}_2 < 70$ mm Hg with $\text{AaDO}_2 \geq 20$ mm Hg)¹ who had physiologic testing between November 2013 and June 2018. The study was approved by St. Michael's Hospital's Research Ethics Board (Toronto).

We inserted an indwelling radial artery catheter and a pulmonary artery catheter and serially evaluated effects of position change, inhaled nitric oxide (iNO), methylene blue (MB) and

combinations thereof (figure 1). We waited a minimum of 10 min after each position change and 20 min after any change in FiO_2 and/or administration of iNO before starting measurements. We measured MB effects hourly after completion of the infusion, up to its reported peak effect at 5 hours (used as the main time point for MB effect reporting).⁶ Our primary outcome was PaO_2 . We also calculated the AaDO_2 , pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR), and assessed changes in these variables, and in mean systemic arterial pressure, mean pulmonary artery pressure (MPAP), pulmonary capillary wedge pressure (PCWP) and cardiac output (CO).

Additional methodological details are provided in the online supplemental information.

RESULTS

We included 26 participants (15 (58%) female, mean (SD) age 54.6 (10.5) years, PaO_2 46.2 (9.6) mm Hg, see online supplemental table 1 for patient characteristics).

All patients received iNO and 18 patients also received MB. Physiologic measurements at baseline and with each intervention are reported in table 1. Changes in key measurements (oxygenation and CO), and the proportion of patients exhibiting PaO_2 improvements of at least 10% and 20%² are shown in table 2 (also see online supplemental figure 1). Significantly higher PaO_2 was seen in the supine compared with the seated position, in the Trendelenburg compared with the supine position, and with iNO (table 2). Addition of MB to iNO did not produce a significant incremental benefit (table 2). There was no significant improvement in PaO_2 5 hours after MB administration (similar results were seen at intervening time points—online supplemental table 2). CO increased in the supine position (as expected due to increased venous return), was unchanged with iNO and increased with MB administered alone, in combination with iNO (compared with no intervention) and when added to iNO (compared with iNO alone) (table 2).

Changes in SVR, PVR and MPAP with each intervention are reported in online supplemental table 3. We found no relationships between baseline characteristics (age, sex, time since HPS diagnosis, PaO_2 (standing), orthodeoxia value, macroaggregated albumin (MAA) shunt fraction or non-invasive shunt fraction) and PaO_2 response to each intervention (online supplemental tables 4, 5).




Figure 1 Intervention protocol. Each intervention is shown in order of occurrence. Stick figures represent patient position. Tests were performed on room air unless otherwise specified. ^aInhaled NO administered at 20 parts per million. ^bMethylene blue effects measured hourly while seated up to 5 hours postintravenous infusion. FiO_2 , fraction of inspired oxygen; NO, nitric oxide.

DISCUSSION

In this physiologic study of 26 patients with moderate to very severe HPS, supine positioning, Trendelenburg positioning and iNO significantly improved oxygenation without negative impacts on CO. To our knowledge, this is the largest report of any of these interventions.

The PaO_2 was 3.3 mm Hg higher in the supine compared with the seated position, and 0.9 mm Hg higher in the Trendelenburg position compared with the supine position (table 2). These position changes are theorised to work through diversion of pulmonary blood flow away from pathologically dilated pulmonary vessels at lung bases, reducing shunt and V/Q mismatch.^{2,7} Although improvements in PaO_2 were small, it is more relevant to consider the potential impact on tissue oxygen delivery (DO_2). DO_2 is proportional to oxygen saturation, which is dependent on PaO_2 through the sigmoidal oxyhaemoglobin dissociation curve. Patients with severe post-transplant hypoxaemia have saturations of 80%–85% or lower,⁵ corresponding to a baseline $PaO_2 \leq 45$ mm Hg. On this steep portion of the oxyhaemoglobin dissociation curve, even small positional PaO_2 improvements could result in clinically significant improvements in saturation and DO_2 . These benefits would need to be weighed against the risk of aspiration and ventilator-associated pneumonia. In routine care, Trendelenburg positioning might also be considered in an HPS exercise programme and/or as a sleep positional strategy to reduce overnight oxygen requirements.

Inhaled NO was the most effective intervention, demonstrating a mean PaO_2 improvement of 12.4 mm Hg and responses of $\geq 10\%$ in over half of patients (table 2). Given that basilar lung vessels may already be maximally dilated,⁸ vasodilatory effects of iNO are thought to be more effective in mid and upper lung units, whereby flow is redistributed

away from basilar lung units, improving V/Q matching and oxygenation. The same mechanism likely explains observed benefits of garlic in HPS, the active compound of which (allicin) is a potent vasodilator.⁹ Unfortunately, we were not able to formally assess regional changes in lung perfusion in order to prove this theory. Overall, our findings suggest that a trial of either iNO or a comparable inhaled vasodilator for severe post-transplant hypoxaemia² (and/or for intra-operative hypoxaemia or as a bridge to transplant) would be reasonable. Ambulatory iNO, longer-acting inhaled vasodilators such as inhaled iloprost,¹⁰ and systemic vasodilators might also be evaluated as chronic medical therapies for HPS.

MB infusion did not produce changes in PaO_2 (table 2). As a potent vasoconstrictor, MB is thought to act by directly vasoconstricting dilated vessels at lung bases to improve V/Q matching, and by restoring impaired hypoxic vasoconstriction in poorly ventilated areas.² There was a significant increase in MPAP but no significant increase in PVR with MB (table 1, online supplemental table 3). In a previous study of seven subjects, Schenk *et al*⁶ reported improvement in oxygenation from 58 mm Hg to 74 mm Hg with MB.⁶ Divergence in our results may be attributable to our more severe disease population (baseline PaO_2 46 mm Hg), which may have been less MB responsive due to end-stage vascular remodelling with resulting vasoplegia of dilated HPS vessels.¹¹ This is supported by Schenk, *et al*'s reported significant PVR increase with MB,⁶ compared with a non-significant change in our cohort. Furthermore, this group reported a significant correlation between improvement in oxygenation and increase in PVR.⁶ However, both Schenk, *et al*'s report and our own demonstrate variable PaO_2 responses, likely reflective of a heterogeneous population, with some but not all patients having preserved

Table 1 Physiologic measurements at baseline and with each intervention

	Room air		Position change				Baseline (upright)* n=18	MB† (upright) n=18	P value
	Baseline (upright)* n=26	Supine n=26		Trendelenburg n=21					
		P value	P value	P value	P value				
Oxygenation									
PaO ₂ (mm Hg)	48.9 (9.6)‡	52.2 (9.0)‡	0.003	52.4 (9.5)	0.002	49.9 (9.1)	51.0 (9.9)	0.34	
AaDO ₂ (mm Hg)	67.4 (31.6)‡	62.3 (27.9)‡	<0.0001	56.7 (8.3)	<0.0001	62.5 (10.6)	61.7 (12.4)	0.62	
Pulmonary haemodynamics§									
CO (L/min)	7.6 (2.1)	8.5 (2.5)	0.0008	8.4 (2.2)	0.005	7.6 (2.3)	8.5 (2.5)	0.01	
MPAP (mm Hg)	14.6 (6.5)	17.8 (5.5)	0.02	20.0 (7.0)	0.001	13.6 (5.2)	17.6 (6.9)	0.0002	
PCWP¶ (mm Hg)	7.7 (5.4)	10.5 (4.4)	0.01	12.6 (5.1)	0.001	7.5 (5.1)	10.1 (5.6)	0.002	
PVR¶ (dyn·s·cm ⁻⁵)	77.6 (48.0)	76.4 (43.4)	0.88	73.9 (35.5)	0.99	68.5 (42.2)	74.0 (47.5)	0.49	
Systemic haemodynamics§									
CVP (mm Hg)	6.8 (4.3)	7.1 (3.3)	0.92	8.8 (4.3)	0.14	7.0 (4.0)	8.3 (4.3)	0.01	
MAP (mm Hg)	92.1 (12.4)	81.7 (13.5)	0.0002	79.0 (12.3)	<0.0001	93.9 (12.6)	101.9 (13.8)	0.007	
SVR (dyn·s·cm ⁻⁵)	977.9 (347.7)	785.9 (344.0)	<0.0001	718.9 (225.8)	<0.0001	999.5 (352.2)	967.2 (332.4)	0.31	
	40% FiO ₂ Baseline (upright)* n=26	Inhaled NO (upright) n=26	P value	Inhaled NO + MB† (upright) n=18				P value	
Oxygenation									
PaO ₂ (mm Hg)	85.8 (28.8)	98.2 (39.3)		103.0 (30.9)	0.0006			0.001	
AaDO ₂ (mm Hg)	157.8 (29.6)	145.2 (40.1)		140.7 (33.6)	0.0009			0.0005	
Pulmonary haemodynamics§									
CO (L/min)	7.0 (1.9)	6.9 (1.9)		8.1 (2.6)	0.71			0.04	
MPAP (mm Hg)	15.4 (5.5)	14.6 (5.6)		17.3 (5.6)	0.23			0.0004	
PCWP¶ (mm Hg)	7.8 (4.9)	8.3 (4.9)		9.8 (5.5)	0.30			0.03	
PVR¶ (dyn·s·cm ⁻⁵)	103.3 (91.0)	76.9 (43.9)		81.1 (57.3)	0.12			0.41	
Systemic haemodynamics§									
CVP (mm Hg)	5.9 (3.9)	5.7 (3.8)		8.3 (5.3)	0.65			0.02	
MAP (mm Hg)	93.5 (15.9)	97.5 (11.5)		107.4 (14.4)	0.07			0.001	
SVR (dyn·s·cm ⁻⁵)	1093.8 (413.5)	1135.0 (334.2)		1101.4 (450.1)	0.22			0.59	

Values reported as mean (SD) and p values calculated using paired t-tests for each intervention; note that some interventions were tested in a smaller number of patients than the baseline comparator; in these cases, only data from patients providing both baseline and intervention data could be compared statistically.

*Although the procedure was started in the supine position, the upright (seated) position is taken as the baseline for each comparison in this table.

†Measured at least 5 hours after MB infusion.

‡Includes one patient on 40% FiO₂ (could not tolerate room air); baseline upright, supine and inhaled NO data points were collected on 40% FiO₂ in this patient; the patient did not undergo Trendelenburg position nor MB testing.

§Two patients did not contribute to haemodynamic data because the pulmonary artery catheter could not be inserted due to recent central venous thrombosis (n=1); and the pulmonary artery catheter malfunctioned (n=1).

¶One additional patient did not contribute pulmonary capillary wedge pressure or PVR data in the Trendelenburg position due to transient catheter malfunction; in an additional two patients, reliable PCWP was not attainable, and we used the diastolic pulmonary artery pressure (PAD) to approximate the PCWP across interventions.

AaDO₂, alveolar-arterial oxygen gradient; CO, cardiac output; CVP, central venous pressure; FiO₂, fraction of inhaled oxygen; MAP, mean arterial pressure; MB, methylene blue; MPAP, mean pulmonary artery pressure; NO, nitric oxide; PaO₂, arterial partial pressure of oxygen; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance.

vasoconstrictor responses. Accordingly, a trial of MB may still be merited in severe post-transplant hypoxaemia, as long as impact on CO (and thus DO₂) is monitored. We also note that adding MB to iNO did not significantly improve PaO₂ compared iNO alone. However, responses were again variable and there was a 13% increase in CO compared with iNO alone, suggesting a DO₂ benefit. Accordingly, we believe that a trial of combined inhaled vasodilator and MB may be merited in severe situations.

Our study has several limitations. The iNO was delivered with FiO₂ of 0.4 as opposed to room air. However, this more closely approximates the real-world scenario in which this

salvage therapy would be used, and effects of all interventions were determined based on comparison to a baseline on the same FiO₂. Although much larger than any prior reports, our sample size remains small and may have been underpowered to detect a small MB effect. We did not pursue molecular biomarker testing to confirm or refute the proposed mechanisms of action of reported agents. We also have not prospectively evaluated the effectiveness nor sustainability of these strategies in the post-transplant context.

In summary, we demonstrated that iNO significantly improves oxygenation in severe HPS, without deleterious effects on CO. Although more data are needed, it may be

Table 2 Change in PaO₂ and CO, by intervention

Intervention	N	Change in PaO ₂ (mm Hg)	Change in PaO ₂ (%)	P value	N (%) with ≥10% PaO ₂ increase	N (%) with ≥20% PaO ₂ increase	Change in CO (L/min)	Change in CO (%)	P value
Positional effects									
Supine vs seated (orthodeoxia)	26	3.3 (1.3, 5.3)	8 (2.8, 13.1)	0.003	9 (35)	3 (12)	0.8 (0.4, 1.2)	11 (5.5, 16.4)	0.0008
Trendelenburg vs supine	21	0.9 (0.4, 1.5)	2 (0.6, 2.9)	0.02	0	0	0.1 (−0.2, 0.4)	2 (−2.0, 5.0)	0.56
MB									
MB* (seated)	18	1.1 (−1.1, 3.2)	2 (−2.4, 7.1)	0.34	3 (17)†	1 (6)	0.8 (0.3, 1.4)	12 (5.7, 18.5)	0.01
MB* (supine)	18	2.3 (0.1, 4.6)	5 (0.5, 9.3)	0.06	6 (33)†	1 (6)	0.6 (−0.1, 1.4)	8 (−0.4, 17.2)	0.13
Inhaled NO									
Inhaled NO (seated)	26	12.4 (6.2, 18.6)	13 (8.0, 18.7)	0.0006	14 (54)	6 (23)	0.0 (−0.3, 0.2)	0 (−3.6, 3.6)	0.71
Inhaled NO + MB									
Inhaled NO + MB* vs Inhaled NO alone (seated)	18	0.8 (−11.5, 13.1)	6 (−3.8, 15.8)	0.90	7 (39)‡	5 (28)	0.9 (0.2, 1.6)	13 (3.7, 21.4)	0.03

Values reported as mean (95% CI) and p values calculated using paired t-tests for each value.

All comparisons are to no intervention, in the same position, on the same fraction of inspired oxygen, unless stated otherwise.

*Measured 5 hours after MB infusion.

†One patient had a ≥10% drop in PaO₂ with each of the following interventions: 17% drop in PaO₂ with MB (seated), 11% drop in PaO₂ with MB (supine), 13% drop in PaO₂ with inhaled NO + MB (seated) (a different patient experienced each of these drops across interventions).

‡Four patients had a ≥10% drop in PaO₂, as follows: drop in PaO₂ of 10%, 13%, 33%, 36%.

CO, cardiac output; MB, methylene blue; NO, nitric oxide; PaO₂, arterial partial pressure of oxygen.

considered early in the management of severe hypoxaemia, whether as a bridge to transplant, during transplant or after. Longer-acting vasodilators require study as possible maintenance therapy for HPS. Small but significant effects were seen with Trendelenburg positioning, but not with MB. However, observed individual variability in effects suggests that pre-transplant testing of all agents in high-risk patients may be helpful in guiding post-transplant management in the event of severe hypoxaemia. Future studies are required to prospectively evaluate the effect of iNO in patients with severe post-transplant hypoxaemia and measure correlations between pre-transplant and post-transplant responses.

Contributors SG and AA-H designed the study and acquired the data. SG and RT analysed the data and drafted the work. All authors revised the work for important intellectual content and approved the final version.

Funding This study was funded by the Michael Locke Term Chair in Knowledge Translation and Rare Lung Disease Research.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study was approved by St. Michael's Hospital's Research Ethics Board (Toronto).

Provenance and peer review Not commissioned; externally peer reviewed.

ORCID iD

Rosalind Tang <http://orcid.org/0000-0002-4379-6673>

REFERENCES

- Krowka MJ, Fallon MB, Kawut SM, *et al.* International liver transplant Society practice guidelines: diagnosis and management of hepatopulmonary syndrome and Portopulmonary hypertension. *Transplantation* 2016;100:1440–52.
- Nayyar D, Man HSJ, Granton J, *et al.* Proposed management algorithm for severe hypoxemia after liver transplantation in the hepatopulmonary syndrome. *Am J Transplant* 2015;15:903–13.
- Fallon MB, Krowka MJ, Brown RS, *et al.* Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. *Gastroenterology* 2008;135:1168–75.
- Iyer VN, Swanson KL, Cartin-Ceba R, *et al.* Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. *Hepatology* 2013;57:2427–35.
- Nayyar D, Man HSJ, Granton J, *et al.* Defining and characterizing severe hypoxemia after liver transplantation in hepatopulmonary syndrome. *Liver Transpl* 2014;20:182–90.
- Schenk P, Madl C, Rezaie-Majid S, *et al.* Methylene blue improves the hepatopulmonary syndrome. *Ann Intern Med* 2000;133:701–6.
- Gómez FP, Martínez-Pallí G, Barberà JA, *et al.* Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. *Hepatology* 2004;40:660–6.
- Fallon MB. Hepatopulmonary syndrome: more than just a matter of tone? *Hepatology* 2006;43:912–4.
- Abrams GA, Fallon MB. Treatment of hepatopulmonary syndrome with Allium sativum L. (garlic): a pilot trial. *J Clin Gastroenterol* 1998;27:232–5.
- Krug S, Seyfarth H-J, Hagendorff A, *et al.* Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia. *Eur J Gastroenterol Hepatol* 2007;19:1140–3.
- Hughes JMB. The hepatopulmonary syndrome: no way out? *Eur Respir J* 2005;25:211–2.